Participants from many countries have already confirmed their presence, including Czech Republic, Poland, Hungary, Slovakia, France, United Kingdom, Denmark, Romania, Turkey, Bosnia and Herzegovina, Germany, Serbia, Japan, China, Italy, Brazil, USA, Canada, etc.
Confirmed Invited Speakers
| Name | Country | Title of the presentation |
|---|---|---|
| R. Fischmeister | Paris, France | Phosphodiesterase type 2: a new target in heart failure? |
| G. Heusch | Essen, Germany | Coronary microvascular injury by ischemia/reperfusion and protection from it. |
| M.S. Suleiman | Bristol, UK | Tribulations of moving from bench to bedside to mend broken heart. |
| L. Kirshenbaum | Winnipeg, Canada | Innate immunity signaling in doxorubicin cardiomyopathy. |
| F. Gallyas | Pecs, Hungary | Repurposing of PARP inhibitors for cardiovascular diseases. |
| M. Czubryt | Winnipeg, Canada | Fibroblast activation as a therapeutic target for cardiac fibrosis. |
| M. Hlavackova | Prague, Czech Republic | Exploring Hif-1α and epitranscriptomic regulation in diabetic cardiomyopathy. |
| M. Michalak | Edmonton, Canada | Interplay between stress sensors and cardiac excitation-contraction coupling. |
| H. S. Buttar | Ontario, Canada | The crucial roles of healthful foods, healthy hut microbiomes, and lifestyle modifications in preventing cardiovascular diseases. |
| M. Delmar | New York, USA | Sudden cardiac arrest in young athletes: the case of ARVC. |
| D. M. Djuric | Belgrade, Republic of Serbia | Comparison of the cardioprotective effects of folic acid in homocysteine-dependent and homocysteine-independent cardiometabolic disease models. |
| N. Nagy | Szeged, Hungary | Investigation of action potential alternans in normal and failed human heart. |
| P. Bencsik | Szeged, Hungary | Therapeutic use of ProtectomiRs (cardioprotective microRNAs) against myocardial ischemia/reperfusion injury. |
| N. Jost | Szeged, Hungary | The invetsigation of the antiarrhythmic effects of novel amiodarone-like mexiletine analogue compounds. |
| A. J. Marian | Texas, USA | DNA double-stranded breaks in the pathogenesis of heart failure. |
| R. Bolli | Kentucky, USA | Current status of cardioprotection, gene therapy, and cell therapy for heart disease. |
| P. Ferdinandy | Budapest, Hungary | Develoment of miRNA therapeutics for cardiprotection. |
| V. Jakovljevic | Kragujevac, Republic of Serbia | Usnic acid as a new protector against doxorubicin-induced cardiotoxicity in rats. |
| N. S. Dhalla | Winnipeg, Canada | Role of Renin-angiotensin system in the loss of adrenergic support in heart failure. |
| B. Ostadal | Prague, Czech Republic | Sex differences in cardiac tolerance to oxygen deprivation - 40 years of cardiovascular research. |
| I. Baczko | Szeged, Hungary | Atrial and ventricular arrhythmogenic remodeling in a large animal model of athlete's heart. |
| A. Varro | Szeged, Hungary | Important species differences in cardiac electrophysiology. |
| M. Morad | South Carolina, USA | Regulation of sarco-tubular, mitochondrial, and nuclear-envelop calcium signaling in human stem-cell derived cardiomyocytes. |
| G. Lopaschuk | Edmonton, Canada | Targeting cardiac fatty acid oxidation to treat heart failure with preserved ejection fraction (HFpEF). |
| I. Rabinovich-Nikitin | Winnipeg, Canada | The effects of shift work on cardiovascular health during pregnancy. |
| S. Dhingra | Winnipeg, Canada | Immunomodulation of allogeneic stem cells for cardiac repair. |
| D. Agrawal | California, USA | Immune mediators and modulators in reducing size and inducing stability of atherosclerotic plaques in carotid artery: novel treatment Strategies. |
| S. Tyagi | Kentucky, USA | The role of the circadian clock system in the transition of HFpEF to the HFrEF. |
| S. Tipparaju | Florida, USA | Nampt activation for protecting the diabetic heart. |
| M. Bartekova | Bratislava, Slovakia | Natural polyphenol quercetin as a potential cardioprotective tool for preventing ischemia-reperfusion injury. |
| P. Kleinbongard | Essen, Germany | Cardioprotection by remote conditioning - an update on the signal transduction pathways. |
| S. Ohta | Tokyo, Japan | Hydrogen medicine from the basic science to clinical trials |
| J. Neckar | Czech Republic | Experimental rat models of HFpEF. |
| P. Krenek | Slovakia | Endothelin system in experimental pulmonary hypertension. |